{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:46:18Z","timestamp":1773697578619,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Program of Guizhou Province Health Committee","award":["gzwkj2024-365"],"award-info":[{"award-number":["gzwkj2024-365"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460039"],"award-info":[{"award-number":["82460039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03757-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:24:20Z","timestamp":1743823460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner"],"prefix":"10.1186","volume":"25","author":[{"given":"Tianzhuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danna","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengmei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"6","key":"3757_CR1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","volume":"97","author":"MR Grunwald","year":"2013","unstructured":"Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol. 2013;97(6):683\u201394.","journal-title":"Int J Hematol"},{"issue":"9865","key":"3757_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet (London England). 2013;381(9865):484\u201395.","journal-title":"Lancet (London England)"},{"issue":"1","key":"3757_CR3","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","volume":"104","author":"SB Liu","year":"2019","unstructured":"Liu SB, Dong HJ, Bao XB, Qiu QC, Li HZ, Shen HJ, Ding ZX, Wang C, Chu XL, Yu JQ, et al. FLT3Impact of -ITD length on prognosis of acute myeloid leukemia. Haematologica. 2019;104(1):e9\u201312.","journal-title":"Haematologica"},{"issue":"5","key":"3757_CR4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35(5):556\u201365.","journal-title":"Invest New Drugs"},{"issue":"2","key":"3757_CR5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","volume":"129","author":"LY Lee","year":"2017","unstructured":"Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M. Preclinical studies of Gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257\u201360.","journal-title":"Blood"},{"issue":"3","key":"3757_CR6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Gilteritinib: first global approval. Drugs. 2019;79(3):331\u20139.","journal-title":"Drugs"},{"issue":"6","key":"3757_CR7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991\u20131001.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"3757_CR8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ajh.24392","volume":"91","author":"V Rajkumar","year":"2016","unstructured":"Rajkumar V. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91(9):965.","journal-title":"Am J Hematol"},{"key":"3757_CR9","doi-asserted-by":"crossref","unstructured":"Nitti M, Piras S, Marinari UM, Moretta L, Pronzato MA, Furfaro AL. HO-1 induction in cancer progression: A matter of cell adaptation. Antioxid (Basel Switzerland). 2017;6(2).","DOI":"10.3390\/antiox6020029"},{"issue":"8","key":"3757_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cas.12712","volume":"106","author":"Q Tan","year":"2015","unstructured":"Tan Q, Wang H, Hu Y, Hu M, Li X, Aodengqimuge, Ma Y, Wei C, Song L. Src\/STAT3-dependent Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer Sci. 2015;106(8):1023\u201332.","journal-title":"Cancer Sci"},{"issue":"5","key":"3757_CR11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.leukres.2015.02.009","volume":"39","author":"X Lin","year":"2015","unstructured":"Lin X, Fang Q, Chen S, Zhe N, Chai Q, Yu M, Zhang Y, Wang Z, Wang J. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK\/c-JUN signaling pathway. Leuk Res. 2015;39(5):544\u201352.","journal-title":"Leuk Res"},{"issue":"7","key":"3757_CR12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1179\/1607845414Y.0000000212","volume":"20","author":"N Zhe","year":"2015","unstructured":"Zhe N, Wang J, Chen S, Lin X, Chai Q, Zhang Y, Zhao J, Fang Q. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. Hematology. 2015;20(7):384\u201391.","journal-title":"Hematology"},{"issue":"7","key":"3757_CR13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","volume":"28","author":"X Niu","year":"2014","unstructured":"Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, Ge Y. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014;28(7):1557\u201360.","journal-title":"Leukemia"},{"key":"3757_CR14","doi-asserted-by":"crossref","first-page":"41950","DOI":"10.1038\/srep41950","volume":"7","author":"J Ma","year":"2017","unstructured":"Ma J, Li X, Su Y, Zhao J, Luedtke DA, Epshteyn V, Edwards H, Wang G, Wang Z, Chu R, et al. Mechanisms responsible for the synergistic antileukemic interactions between ATR Inhibition and cytarabine in acute myeloid leukemia cells. Sci Rep. 2017;7:41950.","journal-title":"Sci Rep"},{"key":"3757_CR15","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang P, Wang Y, Shen Y. Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia. Biomark Res. 2023;11(1).","DOI":"10.1186\/s40364-022-00447-4"},{"key":"3757_CR16","doi-asserted-by":"crossref","unstructured":"Yang Qiu Y, Li M, Chai H, Hua R, Wang S, Waxman Y. Jing. The GSK3\u03b2\/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors. Cell Death Discov. 2023;9(1).","DOI":"10.1038\/s41420-023-01317-0"},{"issue":"1","key":"3757_CR17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-022-03589-z","volume":"20","author":"T Zhang","year":"2022","unstructured":"Zhang T, Fang Q, Liu P, Wang P, Feng C, Wang J. Heme Oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48. J Transl Med. 2022;20(1):394.","journal-title":"J Transl Med"},{"issue":"2","key":"3757_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CAD.0000000000000847","volume":"31","author":"T Zhang","year":"2020","unstructured":"Zhang T, Ma D, Wei D, Lu T, Yu K, Zhang Z, Wang W, Fang Q, Wang J. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia. Anticancer Drugs. 2020;31(2):158\u201368.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"3757_CR19","doi-asserted-by":"crossref","first-page":"11364","DOI":"10.18632\/aging.103174","volume":"12","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Ma D, Li P, Wang P, Liu P, Wei D, Wang J, Qin Z, Fang Q, Wang J. Sirt1 gene confers adriamycin resistance in DLBCL via activating the PCG-1\u03b1 mitochondrial metabolic pathway. Aging. 2020;12(12):11364\u201385.","journal-title":"Aging"},{"issue":"2","key":"3757_CR20","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1039\/C9RA07971H","volume":"10","author":"T Zhang","year":"2020","unstructured":"Zhang T, Wei D, Lu T, Ma D, Yu K, Fang Q, Zhang Z, Wang W, Wang J. CAY10683 and Imatinib have synergistic effects in overcoming Imatinib resistance via HDAC2 Inhibition in chronic myeloid leukemia. RSC Adv. 2020;10(2):828\u201344.","journal-title":"RSC Adv"},{"issue":"22","key":"3757_CR21","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-Mutated acute myeloid leukemia. Clin cancer Research: Official J Am Association Cancer Res. 2019;25(22):6815\u201326.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"3757_CR22","first-page":"6657012","volume":"2021","author":"H Liu","year":"2021","unstructured":"Liu H, Zhang Z, Zhen P, Zhou M. High expression of VSTM2L induced resistance to chemoradiotherapy in rectal cancer through downstream IL-4 signaling. J Immunol Res. 2021;2021:6657012.","journal-title":"J Immunol Res"},{"issue":"9","key":"3757_CR23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","volume":"23","author":"MD Blunt","year":"2017","unstructured":"Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, et al. The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin cancer Research: Official J Am Association Cancer Res. 2017;23(9):2313\u201324.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"21","key":"3757_CR24","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","volume":"27","author":"PY Dumas","year":"2021","unstructured":"Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, Bidet A, Martineau D, Fernandez S, Leguay T, et al. Dual Inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic Niche-Driven resistance mechanisms in FLT3-ITD acute myeloid leukemia. Clin Cancer Res. 2021;27(21):6012\u201325.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3757_CR25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1158\/1078-0432.CCR-17-2587","volume":"24","author":"T Muliaditan","year":"2018","unstructured":"Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, et al. Repurposing Tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(7):1617\u201328.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"3757_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13402-012-0105-5","volume":"35","author":"JR Tsai","year":"2012","unstructured":"Tsai JR, Wang HM, Liu PL, Chen YH, Yang MC, Chou SH, Cheng YJ, Yin WH, Hwang JJ, Chong IW. High expression of Heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr). 2012;35(6):461\u201371.","journal-title":"Cell Oncol (Dordr)"},{"key":"3757_CR27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/1471-2407-13-516","volume":"13","author":"SJ Noh","year":"2013","unstructured":"Noh SJ, Bae JS, Jamiyandorj U, Park HS, Kwon KS, Jung SH, Youn HJ, Lee H, Park BH, Chung MJ, et al. Expression of nerve growth factor and Heme oxygenase-1 predict poor survival of breast carcinoma patients. BMC Cancer. 2013;13:516.","journal-title":"BMC Cancer"},{"issue":"26","key":"3757_CR28","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3748\/wjg.v20.i26.8572","volume":"20","author":"YS Liu","year":"2014","unstructured":"Liu YS, Li HS, Qi DF, Zhang J, Jiang XC, Shi K, Zhang XJ, Zhang XH. Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin. World J Gastroenterol. 2014;20(26):8572\u201382.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3757_CR29","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2353\/ajpath.2006.051365","volume":"169","author":"H Was","year":"2006","unstructured":"Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C, Leger JJ, Lackowska B, Grochot A, Bojkowska K, et al. Overexpression of Heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol. 2006;169(6):2181\u201398.","journal-title":"Am J Pathol"},{"issue":"10","key":"3757_CR30","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1078-0432.CCR-04-2159","volume":"11","author":"PO Berberat","year":"2005","unstructured":"Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, K\u00fcnzli B, Autschbach F, Meuer S, B\u00fcchler MW, Friess H. Inhibition of Heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin cancer Research: Official J Am Association Cancer Res. 2005;11(10):3790\u20138.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"24","key":"3757_CR31","doi-asserted-by":"crossref","first-page":"21631","DOI":"10.1074\/jbc.M300609200","volume":"278","author":"G Helbig","year":"2003","unstructured":"Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem. 2003;278(24):21631\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"3757_CR32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers3021605","volume":"3","author":"SA Rushworth","year":"2011","unstructured":"Rushworth SA, Macewan DJ. The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers (Basel). 2011;3(2):1605\u201321.","journal-title":"Cancers (Basel)"},{"key":"3757_CR33","doi-asserted-by":"crossref","first-page":"823377","DOI":"10.3389\/fonc.2022.823377","volume":"12","author":"P Gao","year":"2022","unstructured":"Gao P, Ren G, Liang J, Liu J. STAT6 upregulates NRP1 expression in endothelial cells and promotes angiogenesis. Front Oncol. 2022;12:823377.","journal-title":"Front Oncol"},{"issue":"3","key":"3757_CR34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/leu.2017.261","volume":"32","author":"P Pe\u00f1a-Mart\u00ednez","year":"2018","unstructured":"Pe\u00f1a-Mart\u00ednez P, Eriksson M, Ramakrishnan R, Chapellier M, H\u00f6gberg C, Orsmark-Pietras C, Richter J, Andersson A, Fioretos T, J\u00e4r\u00e5s M. Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner. Leukemia. 2018;32(3):588\u201396.","journal-title":"Leukemia"},{"key":"3757_CR35","doi-asserted-by":"crossref","unstructured":"Park S, Griesenauer B, Jiang H, Adom D, Mehrpouya-Bahrami P, Chakravorty S, Kazemian M, Imam T, Srivastava R, Hayes TA et al. Granzyme A-producing T helper cells are critical for acute graft-versus-host disease. JCI Insight. 2020;5(18).","DOI":"10.1172\/jci.insight.124465"},{"issue":"5","key":"3757_CR36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2326-6066.CIR-16-0168","volume":"5","author":"SA Leon-Cabrera","year":"2017","unstructured":"Leon-Cabrera SA, Molina-Guzman E, Delgado-Ramirez YG, V\u00e1zquez-Sandoval A, Ledesma-Soto Y, P\u00e9rez-Plasencia CG, Chirino YI, Delgado-Buenrostro NL, Rodr\u00edguez-Sosa M, Vaca-Paniagua F, et al. Lack of STAT6 attenuates inflammation and drives protection against early steps of Colitis-Associated colon cancer. Cancer Immunol Res. 2017;5(5):385\u201396.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3757_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cyto.2008.01.016","volume":"42","author":"WJ Zhang","year":"2008","unstructured":"Zhang WJ, Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Xu SB, Zhang Y, Yuan J, Gerhard GS, et al. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008;42(1):39\u201347.","journal-title":"Cytokine"},{"issue":"3","key":"3757_CR38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.critrevonc.2005.08.005","volume":"57","author":"HA Bruns","year":"2006","unstructured":"Bruns HA, Kaplan MH. The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol. 2006;57(3):245\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"3757_CR39","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, et al. Genetic landscapes of relapsed and refractory diffuse large B-Cell lymphomas. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(9):2290\u2013300.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"3757_CR40","doi-asserted-by":"crossref","unstructured":"Sylvain Garciaz M-A, Hospital. FMS-Like tyrosine kinase 3 inhibitors in the treatment of acute myeloid leukemia: an update on the emerging evidence and safety profile. Onco Targets Ther. 2023;16(0).","DOI":"10.2147\/OTT.S236740"},{"key":"3757_CR41","doi-asserted-by":"crossref","unstructured":"Tecik M, Adan A. Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches. Onco Targets Ther. 2022;15(0).","DOI":"10.2147\/OTT.S384293"},{"key":"3757_CR42","doi-asserted-by":"crossref","unstructured":"Motoki Eguchi Y, Minami A, Kuzume. Sunggi Chi. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines. 2020;8(8).","DOI":"10.3390\/biomedicines8080245"},{"key":"3757_CR43","doi-asserted-by":"crossref","unstructured":"Stephen SY, Lam, Anskar YH, Leung. Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-Mutated AML. Int J Mol Sci 2020;21(4).","DOI":"10.3390\/ijms21041537"},{"key":"3757_CR44","doi-asserted-by":"crossref","unstructured":"Catherine C, Smith MJ, Levis AE, Perl JE, Hill. Matt Rosales, Erkut Bahceci. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv 2022;6(7).","DOI":"10.1182\/bloodadvances.2021006489"},{"key":"3757_CR45","doi-asserted-by":"crossref","unstructured":"Ghiaur G, Mark Levis. Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment. Hematol Oncol Clin North Am. 2017;31(4).","DOI":"10.1016\/j.hoc.2017.04.005"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03757-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:26:04Z","timestamp":1743823564000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3757"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03757-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal care and ethical committee of Guizhou Medical University approved our protocols. All animal-handling procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and followed the guidelines of the Animal Welfare Act. According to the Helsinki Declaration, the informed consent was first obtained in writing. All patients volunteered to participate in this experiment. All patient information has been kept confidential.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}